Prof. Hagit Eldar-Finkelman

Human Molecular Genetics Biochemistry
Medicine Dean & Assoc. Deans
גנטיקה מולקולרית של אדם וביוכימיה סגל אקדמי בכיר
Prof. Hagit Eldar-Finkelman
Phone: 03-6405307
Another phone: 03-6405308
Fax: 03-6408749
Office: Sackler School of Medicine, 1012


Professor, Human Molecular Genetics & Biochemistry, Sackler Faculty of Medicine, Tel Aviv University

Chair, Sackler Committee for Ph.D. Graduate Studies




1994 – 1998    Postdoctoral work with Nobel Laureate Professor Edwin G Krebs School of Medicine, University of Washington (UW)
1993          Doctor of Philosophy (Ph.D.), Life Science Weizmann Institute of Science
1988  Recipient of the British Council Award to conduct research in biological nuclear magnetic resonance University of Oxford
1988 M.Sc., Chemsitry Weizmann Institute of Science
1982 B.Sc., Chemistry The Hebrew University




The research in Eldar-Finkelman’s laboratory is focused on the development of new innovative therapeutics addressing unmet needs in the cancer neurodegenerative disorders arena. A particular interest is given to the protein kinases such as glycogen synthase kinase-3 (GSK-3), and Abl as prominent drug targets. We combine expertise in chemistry, biology, and computational modeling to design drugs with unique inhibition modality. Our goal is to ultimately produce beneficial therapeutics for clinical practice.

Publications and Grants


:Recent Publications



Licht-Murava, A., Paz, R., Vaks L., Avrahami, L., Plotkin,B.,  Eisenstein, M., Eldar-Finkelman,H. (2016) A unique type of GSK-3 inhibitor brings new opportunities to the clinic. Sci Signal,  9(454), ra110.


Avrahami, L., Paz, R., Dominko, Silva Hecimovic, S., Bucci, C., Eldar-Finkelman, H. (2020) GSK-3-TSC axis governs lysosomal acidification through autophagy and endocytic pathways. Cell. Signal. 71: 109597. 


Rippin, I., Khazanov, N.,  Ben Joseph, S., Kudinov, T.,  Berent, E., Arciniegas Ruiz, S-M., Marciano, D., Levy, L.,  Gruzman, A., Senderowitz, Eldar-Finkelman, H. (2020) Discovery and design of novel small molecule GSK-3 inhibitors targeting the substrate binding site. (2021) International Journal of Molecular Science, 21: 8709.


Rippin, I., Boner, K., Joseph, S., Sarsor, A., Vaks, L., Eldar-Finkelman, H. Inhibition of GSK-3 ameliorates the pathogenesis of Huntington's disases. (2021) Neurobiology of Disease, 154, 105336.


Rippin, I. Eldar-Finkelman H, Rippin, I.  2021 Mechanisms and therapeutic implications of GSK-3 in  treating Neurodegeneration. Cells, 10(2): 262.

Tel Aviv University makes every effort to respect copyright. If you own copyright to the content contained here and / or the use of such content is in your opinion infringing, Contact us as soon as possible >>
Tel Aviv University
P.O. Box 39040, Tel Aviv 6997801